Marktanalyse - Prescription Pharmaceutical Market Sales Overview – Analysis of prescription pharmaceutical sales across 12 major markets
Datamonitor
12 / 2010
302 Seiten
| Typ: | Marktanalyse |
| Sprache: | Englisch |
| Regionen: | Europa, Asien / Pazifik, Mittlerer Osten / Afrika, Nordamerika / USA, Australien, Mittel- / Südamerika |
| Verfügbarkeit: | verfügbar |
Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:
Introduction
Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled $555bn in 2009, having grown by 6.3% during 2008—09, and at a compound annual growth rate (CAGR) of 5.6% between 2005 and 2009.
Features and benefits
* Analyzes the size and growth (in terms of volume and value) of the 12 major prescription pharmaceutical markets* Examines the prescription pharmaceutical sales growth trends across the various different therapy areas* Assesses the leading prescription pharmaceutical brands across the each of the 12 major pharma markets* Profiles the leading multinational and domestic pharma companies operating in each of the 12 major pharma markets.
Highlights
The US prescription pharmaceutical market generated half (50.3%) of the sales of the 12 markets analyzed, with $279bn in 2009, with sales having grown by 5.0% (CAGR, 2005—09) and 5.5% (2008—09). However, future sales growth will be shaped by three key events: the US economic downturn, healthcare reform and the patent cliff.The five major European markets (UK, Germany, France, Italy and Spain) generated sales of $143bn in 2009. However, ongoing austerity measures targeted at reducing healthcare expenditure, through driving up generic penetration as well as price cuts (on branded and generic drugs) will dampen growth going forward.Growth in the emerging markets is driven by their rapidly growing economies and populations; expansion of healthcare systems and health insurance policies, increasing access to drugs; and the emergence of middle classes with disposable incomes, who are more likely to spend money on branded generics and branded pharmaceuticals.
Your key questions answered
* Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2015* Quantify the size and growth of the 12 major pharmaceutical markets, analyzing key therapy areas, brands and companies* Assess drivers and resistors of the prescription pharmaceutical market
Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled $555bn in 2009, having grown by 6.3% during 2008—09, and at a compound annual growth rate (CAGR) of 5.6% between 2005 and 2009.
Features and benefits
* Analyzes the size and growth (in terms of volume and value) of the 12 major prescription pharmaceutical markets* Examines the prescription pharmaceutical sales growth trends across the various different therapy areas* Assesses the leading prescription pharmaceutical brands across the each of the 12 major pharma markets* Profiles the leading multinational and domestic pharma companies operating in each of the 12 major pharma markets.
Highlights
The US prescription pharmaceutical market generated half (50.3%) of the sales of the 12 markets analyzed, with $279bn in 2009, with sales having grown by 5.0% (CAGR, 2005—09) and 5.5% (2008—09). However, future sales growth will be shaped by three key events: the US economic downturn, healthcare reform and the patent cliff.The five major European markets (UK, Germany, France, Italy and Spain) generated sales of $143bn in 2009. However, ongoing austerity measures targeted at reducing healthcare expenditure, through driving up generic penetration as well as price cuts (on branded and generic drugs) will dampen growth going forward.Growth in the emerging markets is driven by their rapidly growing economies and populations; expansion of healthcare systems and health insurance policies, increasing access to drugs; and the emergence of middle classes with disposable incomes, who are more likely to spend money on branded generics and branded pharmaceuticals.
Your key questions answered
* Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2015* Quantify the size and growth of the 12 major pharmaceutical markets, analyzing key therapy areas, brands and companies* Assess drivers and resistors of the prescription pharmaceutical market
Executive Summary
Introduction
Strategic scoping and focus
12 Major markets — Key Findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Related reports
4. 12 MAJOR MARKETS — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
12 Major markets — Key Findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
12 Major markets — Pharmaceutical market size
The US pharmaceutical market while the largest will decline through 2015
Cost-containment policies throughout Europe translate in modest growth
Brand loyal Japan aims to boost its generics industry
Australia’s small pharmaceutical market is also undertaking cost-cutting measures
The emerging markets showed the fastest growth rates
Global forecast sales for the top 50 pharma companies
12 Major markets — Leading therapy areas
The CNS and cardiovascular markets will experience sales declines out to 2015 due to increasing generic competition
Metabolic, oncology and oncology markets driven by biologic sales growth
Chinese medicines are the fastest growing drug group
12 Major markets — Leading pharmaceutical brands
Lipitor is to experience a dramatic loss in sales due to its looming patent expiry
Plavix is the industry-leading antithrombotic and is supported by a wealth of post-launch data
Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are forecast to decline
12 Major markets — Leading pharmaceutical companies
Pfizer
Merck & Co.
AstraZeneca
GlaxoSmithKline
Novartis
Sanofi-Aventis
Roche
Johnson & Johnson
Eli Lilly
Takeda
3. US — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
US — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
US — Pharmaceutical market size
US — Leading therapy areas
Metabolic drugs exhibited the strongest sales growth during 2005—09
Central nervous system drugs hold the largest value share of the US market
Cardiovascular drugs saw declining sales
Leading therapy areas out to 2015 (for the top 50 pharma companies)
US — Leading pharmaceutical brands
Lipitor has suffered sales erosion die to availability of other generic statins
Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are forecast to decline
Plavix is the industry-leading antithrombotic and is supported by a wealth of post-launch data
US — Leading pharmaceutical companies
The top 10 pharmaceutical companies in the US
Forecast sales for the top 10 pharmaceutical companies in 2015
The top 10 US-based pharmaceutical companies
Pfizer
Merck & Co.
Johnson & Johnson
4. JAPAN — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Japan — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Japan — Pharmaceutical market size
Japan — Leading therapy areas
Cardiovascular drugs hold the largest value share of the Japanese market
Immunology and inflammation drugs have exhibited the fastest annual growth following approval of biologic drugs
Oncology drugs will drive market growth out to 2015
The musculoskeletal market is contracting due to intensifying generic competition
Leading therapy areas out to 2015 (for the top 50 pharma companies)
Japan — Leading prescription pharmaceutical brands
Blopress is the highest selling brand in Japan but its position may be in jeopardy from 2012 onwards
Diovan has been growing strongly thanks to numerous indication approvals
Lipitor maintains growth despite the availability of cheaper generic statins
Japan — Leading pharmaceutical companies
Roche and Eisai have experienced particularly strong growth in Japan
Leading companies out to 2015
The leading domestic companies are exhibiting modest growth rates
5. FRANCE — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
France — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
France — Pharmaceutical market size
France — Leading therapy areas
Central nervous system was the largest therapy area in terms of sales
Oncology drugs have shown the fastest growth rates
Gastroenterology drugs have shown the sharpest decline in growth rates
France — Leading pharmaceutical brands
Plavix is the top-selling pharmaceutical brand, although its position will be jeopardized due to intensifying generic competition
Lipitor will see a sharp decline in sales following the imminent patent expiry in 2011
Avastin’s impressive growth rates are set to continue in the future
France — Leading pharmaceutical companies
Sanofi-Aventis is the largest pharmaceutical company in France
Mylan is the largest generics company in France
The top 10 France-based pharmaceutical companies
6. GERMANY — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Germany — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Germany — Pharmaceutical market size
Germany — Leading therapy areas
CNS drugs held the largest share of the German market value
Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009
Oncology drugs exhibited the strongest sales over 2005—09
Gastroenterology market is contracting due to significant generic competition
Germany — Leading pharmaceutical brands
Humira’s leading position is likely to be maintained in the future
Despite patent expiry in 2010, Enbrel’s growth is set to continue
Herceptin’s strong sales growth is attributed to superior efficacy and unbeatable gold-standard status
Germany — Leading pharmaceutical companies
Most of the top 10 companies have exhibited near-flat growth rates, with the notable exception of Novartis and Roche
The leading domestic companies are largely generics or parallel importers
7. ITALY — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Italy — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Italy — Pharmaceutical market size
Italy — Leading therapy areas
Cardiovascular drugs collectively hold the largest market share but have exhibited flat sales growth
Musculoskeletal drugs exhibited the fastest sales and volume growth due to rapid uptake of a new first-in-class drug
Gastroenterology market is contracting due to intensifying generic competition
Italy — Leading pharmaceutical brands
Lipitor is the top selling brand and is set to maintain its position in Italy due to strong brand loyalty
Herceptin’s strong sales growth is attributed to superior efficacy and unbeatable gold standard status
Eprex has exhibited solid growth although its future position remains uncertain due to fierce competition
Italy — Leading pharmaceutical companies
The leading international companies hold the lion’s share of the Italian pharmaceutical market
The leading domestic companies are exhibiting faster growth rates
8. SPAIN — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Spain — key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Spain — pharmaceutical market size
Spain — leading therapy areas
CNS was the largest therapy area in terms of sales The CNS market was the largest therapy area in Spain, generating $4.2bn in sales during 2009, with a sales CAGR of 6.6% from 2005 to 2009, and an annual growth rate of 4.2% (2008—09) (MIDAS sales data, IMS Health, March 2010). This is largely attributed to brands such as Risperdal (risperidone, Johnson & Johnson), Zyprexa (olanzapine, Eli Lilly), and Lyrica (pregabalin, Pfizer), with all three drugs featured among the 20 top selling pharmaceutical brands in Spain.
The musculoskeletal market is being driven by rapid uptake of osteoporosis treatments
The immunology and inflammation market is being driven by several innovative drugs
The gastroenterology market is contracting due to intensifying generic competition
Spain — leading pharmaceutical brands
Lipitor is the top selling brand but its looming patent expiry may jeopardize its leading position
Plavix is starting to face considerable generic competition in Spain
Humira’s strong position is likely to be maintained in the future
Spain — leading pharmaceutical companies
Pfizer was the largest pharmaceutical company in Spain
Roche's sales have been driven by the rapid uptake of monoclonal antibodies
The top 10 Spain-based pharmaceutical companies
9. UK — PRESCRIPTION PHARMACEUTICAL SALES ANALYSISUK — KEY FINDINGS
[Missing title]
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
UK — Pharmaceutical market size
UK — Leading therapy areas
Central nervous system drugs hold the largest share of the UK market value
Oncology drugs exhibited the strongest sales during 2005—09
Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009
Gastroenterology and cardiovascular drugs saw declining sales
UK — Leading pharmaceutical brands
Leading brand Seretide may face competition from faster-growing Symbicort
Lipitor has begun to suffer from sales erosion from other generic statins
Enbrel’s solid growth is attributed to its superior efficacy and having secured approval for multiple indications
UK — Leading pharmaceutical companies
The top 10 companies struggle to maintain growth momentum
The leading domestic companies experience impressive growth
10. AUSTRALIA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Australia — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Australia — Pharmaceutical market size
Australia — Leading therapy areas
Cardiovascular drugs hold the largest share of the Australian market value
Central nervous system products hold the second-largest share of the Australian market value
Musculoskeletal drugs exhibited the strongest growth in sales in 2005—09 and 2008—09
The hematology class experienced the most rapid decline in growth
Australia — Leading pharmaceutical brands
Lipitor achieved by far the highest sales in Australia in 2009, but generics are expected in 2012
Crestor experiences a huge uptake in sales but may face price cuts and uncertain patent protection
Nexium’s sales are going strong despite its price being linked to generic omeprazole
Australia — Leading pharmaceutical companies
Leading international companies active in Australia account for 63% of the pharmaceutical market
Leading Australian companies only make up 7% of the Australian pharmaceutical market
11. BRAZIL — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Brazil — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Brazil — Pharmaceutical market size
Brazil — Leading therapy areas
Central nervous system was the largest therapy area in terms of sales
Musculoskeletal drugs have shown the fastest growth rates
Urology and metabolic have shown the slowest growth rates
Brazil — Leading pharmaceutical brands
Top-selling drug Dorflex sees its franchise extended with follow-up product
Cialis to maintain momentum thanks to lifecycle management strategy
Lipitor is expected to continue reaching high sales even after patent expiration
Brazil — Leading pharmaceutical companies
Sanofi-Aventis is now the leading pharma company in Brazil following its acquisition of Medley
Novartis’s Brazilian retail sales growth driven by its Diovan franchise
The leading domestic companies are exhibiting double-digit growth rates
12. RUSSIA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Russia — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Russia — Pharmaceutical market size
Russia — Leading therapy areas
Central nervous system drugs hold the largest share of the Russian market value
Infectious disease drugs exhibited the strongest annual sales growth (2008—09)
Hematology drugs showed the fastest growth in terms of sales CAGR (2005—09)
Russia — Leading pharmaceutical brands
Velcade was the top selling brand in Russia
Octavi exhibited the strongest sales CAGR of the top 20 brands, but faces competition from its follow-on product
Glivec’s gold-standard position drives uptake
Russia — Leading pharmaceutical companies
The leading international companies offer both innovative therapies and generic products
Domestic companies offer largely generic and consumer healthcare products
13. INDIA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
India — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
India — Pharmaceutical market size
India — Leading therapy areas
Infectious diseases drugs hold the largest value share of the Indian market
Musculoskeletal drugs have exhibited the fastest annual growth
Uptake of oncology drugs is growing rapidly albeit from a very low base
India — Leading prescription pharmaceutical brands
Phensedyl cough and Corex dominated the respiratory market in India
Human Mixtard 30/70 has been growing strongly as diabetes rates increase
India — Leading pharmaceutical companies
Leading international companies in India
The leading domestic companies are exhibiting modest growth rates
14. CHINA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
China — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
China — Pharmaceutical market size
China — Leading therapy areas
Infectious diseases drugs hold the largest share of the Chinese market value
Traditional Chinese medicines (TCMs) exhibited the strongest sales during 2005—09
China — Leading pharmaceutical brands
Shu Xue Ning achieved by far the highest sales in China in 2009
Ke Lin Ao
Plavix — FDA ‘black box’ warning may influence its sales in China
China — Leading pharmaceutical companies
The leading international companies held almost 18% of Chinese value market in 2009
The leading domestic companies experienced impressive growth
Shandong Qilu Pharma
Jiangsu Yangzijiang Pharma
15. BIBLIOGRAPHY
[Missing title]
Publications and online articles
Datamonitor reports and products
US — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Japan — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
France — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Germany — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Italy — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Spain — Prescription pharmaceutical sales
Publications and online articles
Datamonitor reports and products
UK — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Australia — Prescription pharmaceutical sales analysis
Publications and online articles
Brazil — Prescription pharmaceutical sales analysis
Publications and online articles
Russia — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
India — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
China — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
APPENDIX
Datamonitor prescription pharmaceutical definition and therapy area classification
Introduction
Strategic scoping and focus
12 Major markets — Key Findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Related reports
4. 12 MAJOR MARKETS — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
12 Major markets — Key Findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
12 Major markets — Pharmaceutical market size
The US pharmaceutical market while the largest will decline through 2015
Cost-containment policies throughout Europe translate in modest growth
Brand loyal Japan aims to boost its generics industry
Australia’s small pharmaceutical market is also undertaking cost-cutting measures
The emerging markets showed the fastest growth rates
Global forecast sales for the top 50 pharma companies
12 Major markets — Leading therapy areas
The CNS and cardiovascular markets will experience sales declines out to 2015 due to increasing generic competition
Metabolic, oncology and oncology markets driven by biologic sales growth
Chinese medicines are the fastest growing drug group
12 Major markets — Leading pharmaceutical brands
Lipitor is to experience a dramatic loss in sales due to its looming patent expiry
Plavix is the industry-leading antithrombotic and is supported by a wealth of post-launch data
Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are forecast to decline
12 Major markets — Leading pharmaceutical companies
Pfizer
Merck & Co.
AstraZeneca
GlaxoSmithKline
Novartis
Sanofi-Aventis
Roche
Johnson & Johnson
Eli Lilly
Takeda
3. US — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
US — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
US — Pharmaceutical market size
US — Leading therapy areas
Metabolic drugs exhibited the strongest sales growth during 2005—09
Central nervous system drugs hold the largest value share of the US market
Cardiovascular drugs saw declining sales
Leading therapy areas out to 2015 (for the top 50 pharma companies)
US — Leading pharmaceutical brands
Lipitor has suffered sales erosion die to availability of other generic statins
Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are forecast to decline
Plavix is the industry-leading antithrombotic and is supported by a wealth of post-launch data
US — Leading pharmaceutical companies
The top 10 pharmaceutical companies in the US
Forecast sales for the top 10 pharmaceutical companies in 2015
The top 10 US-based pharmaceutical companies
Pfizer
Merck & Co.
Johnson & Johnson
4. JAPAN — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Japan — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Japan — Pharmaceutical market size
Japan — Leading therapy areas
Cardiovascular drugs hold the largest value share of the Japanese market
Immunology and inflammation drugs have exhibited the fastest annual growth following approval of biologic drugs
Oncology drugs will drive market growth out to 2015
The musculoskeletal market is contracting due to intensifying generic competition
Leading therapy areas out to 2015 (for the top 50 pharma companies)
Japan — Leading prescription pharmaceutical brands
Blopress is the highest selling brand in Japan but its position may be in jeopardy from 2012 onwards
Diovan has been growing strongly thanks to numerous indication approvals
Lipitor maintains growth despite the availability of cheaper generic statins
Japan — Leading pharmaceutical companies
Roche and Eisai have experienced particularly strong growth in Japan
Leading companies out to 2015
The leading domestic companies are exhibiting modest growth rates
5. FRANCE — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
France — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
France — Pharmaceutical market size
France — Leading therapy areas
Central nervous system was the largest therapy area in terms of sales
Oncology drugs have shown the fastest growth rates
Gastroenterology drugs have shown the sharpest decline in growth rates
France — Leading pharmaceutical brands
Plavix is the top-selling pharmaceutical brand, although its position will be jeopardized due to intensifying generic competition
Lipitor will see a sharp decline in sales following the imminent patent expiry in 2011
Avastin’s impressive growth rates are set to continue in the future
France — Leading pharmaceutical companies
Sanofi-Aventis is the largest pharmaceutical company in France
Mylan is the largest generics company in France
The top 10 France-based pharmaceutical companies
6. GERMANY — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Germany — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Germany — Pharmaceutical market size
Germany — Leading therapy areas
CNS drugs held the largest share of the German market value
Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009
Oncology drugs exhibited the strongest sales over 2005—09
Gastroenterology market is contracting due to significant generic competition
Germany — Leading pharmaceutical brands
Humira’s leading position is likely to be maintained in the future
Despite patent expiry in 2010, Enbrel’s growth is set to continue
Herceptin’s strong sales growth is attributed to superior efficacy and unbeatable gold-standard status
Germany — Leading pharmaceutical companies
Most of the top 10 companies have exhibited near-flat growth rates, with the notable exception of Novartis and Roche
The leading domestic companies are largely generics or parallel importers
7. ITALY — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Italy — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Italy — Pharmaceutical market size
Italy — Leading therapy areas
Cardiovascular drugs collectively hold the largest market share but have exhibited flat sales growth
Musculoskeletal drugs exhibited the fastest sales and volume growth due to rapid uptake of a new first-in-class drug
Gastroenterology market is contracting due to intensifying generic competition
Italy — Leading pharmaceutical brands
Lipitor is the top selling brand and is set to maintain its position in Italy due to strong brand loyalty
Herceptin’s strong sales growth is attributed to superior efficacy and unbeatable gold standard status
Eprex has exhibited solid growth although its future position remains uncertain due to fierce competition
Italy — Leading pharmaceutical companies
The leading international companies hold the lion’s share of the Italian pharmaceutical market
The leading domestic companies are exhibiting faster growth rates
8. SPAIN — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Spain — key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Spain — pharmaceutical market size
Spain — leading therapy areas
CNS was the largest therapy area in terms of sales The CNS market was the largest therapy area in Spain, generating $4.2bn in sales during 2009, with a sales CAGR of 6.6% from 2005 to 2009, and an annual growth rate of 4.2% (2008—09) (MIDAS sales data, IMS Health, March 2010). This is largely attributed to brands such as Risperdal (risperidone, Johnson & Johnson), Zyprexa (olanzapine, Eli Lilly), and Lyrica (pregabalin, Pfizer), with all three drugs featured among the 20 top selling pharmaceutical brands in Spain.
The musculoskeletal market is being driven by rapid uptake of osteoporosis treatments
The immunology and inflammation market is being driven by several innovative drugs
The gastroenterology market is contracting due to intensifying generic competition
Spain — leading pharmaceutical brands
Lipitor is the top selling brand but its looming patent expiry may jeopardize its leading position
Plavix is starting to face considerable generic competition in Spain
Humira’s strong position is likely to be maintained in the future
Spain — leading pharmaceutical companies
Pfizer was the largest pharmaceutical company in Spain
Roche's sales have been driven by the rapid uptake of monoclonal antibodies
The top 10 Spain-based pharmaceutical companies
9. UK — PRESCRIPTION PHARMACEUTICAL SALES ANALYSISUK — KEY FINDINGS
[Missing title]
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
UK — Pharmaceutical market size
UK — Leading therapy areas
Central nervous system drugs hold the largest share of the UK market value
Oncology drugs exhibited the strongest sales during 2005—09
Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009
Gastroenterology and cardiovascular drugs saw declining sales
UK — Leading pharmaceutical brands
Leading brand Seretide may face competition from faster-growing Symbicort
Lipitor has begun to suffer from sales erosion from other generic statins
Enbrel’s solid growth is attributed to its superior efficacy and having secured approval for multiple indications
UK — Leading pharmaceutical companies
The top 10 companies struggle to maintain growth momentum
The leading domestic companies experience impressive growth
10. AUSTRALIA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Australia — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
Australia — Pharmaceutical market size
Australia — Leading therapy areas
Cardiovascular drugs hold the largest share of the Australian market value
Central nervous system products hold the second-largest share of the Australian market value
Musculoskeletal drugs exhibited the strongest growth in sales in 2005—09 and 2008—09
The hematology class experienced the most rapid decline in growth
Australia — Leading pharmaceutical brands
Lipitor achieved by far the highest sales in Australia in 2009, but generics are expected in 2012
Crestor experiences a huge uptake in sales but may face price cuts and uncertain patent protection
Nexium’s sales are going strong despite its price being linked to generic omeprazole
Australia — Leading pharmaceutical companies
Leading international companies active in Australia account for 63% of the pharmaceutical market
Leading Australian companies only make up 7% of the Australian pharmaceutical market
11. BRAZIL — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Brazil — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Brazil — Pharmaceutical market size
Brazil — Leading therapy areas
Central nervous system was the largest therapy area in terms of sales
Musculoskeletal drugs have shown the fastest growth rates
Urology and metabolic have shown the slowest growth rates
Brazil — Leading pharmaceutical brands
Top-selling drug Dorflex sees its franchise extended with follow-up product
Cialis to maintain momentum thanks to lifecycle management strategy
Lipitor is expected to continue reaching high sales even after patent expiration
Brazil — Leading pharmaceutical companies
Sanofi-Aventis is now the leading pharma company in Brazil following its acquisition of Medley
Novartis’s Brazilian retail sales growth driven by its Diovan franchise
The leading domestic companies are exhibiting double-digit growth rates
12. RUSSIA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Russia — Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
Russia — Pharmaceutical market size
Russia — Leading therapy areas
Central nervous system drugs hold the largest share of the Russian market value
Infectious disease drugs exhibited the strongest annual sales growth (2008—09)
Hematology drugs showed the fastest growth in terms of sales CAGR (2005—09)
Russia — Leading pharmaceutical brands
Velcade was the top selling brand in Russia
Octavi exhibited the strongest sales CAGR of the top 20 brands, but faces competition from its follow-on product
Glivec’s gold-standard position drives uptake
Russia — Leading pharmaceutical companies
The leading international companies offer both innovative therapies and generic products
Domestic companies offer largely generic and consumer healthcare products
13. INDIA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
India — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
India — Pharmaceutical market size
India — Leading therapy areas
Infectious diseases drugs hold the largest value share of the Indian market
Musculoskeletal drugs have exhibited the fastest annual growth
Uptake of oncology drugs is growing rapidly albeit from a very low base
India — Leading prescription pharmaceutical brands
Phensedyl cough and Corex dominated the respiratory market in India
Human Mixtard 30/70 has been growing strongly as diabetes rates increase
India — Leading pharmaceutical companies
Leading international companies in India
The leading domestic companies are exhibiting modest growth rates
14. CHINA — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
China — Key findings
Pharmaceutical market size
Leading therapy areas
Leading prescription pharmaceutical brands
Leading pharmaceutical companies
China — Pharmaceutical market size
China — Leading therapy areas
Infectious diseases drugs hold the largest share of the Chinese market value
Traditional Chinese medicines (TCMs) exhibited the strongest sales during 2005—09
China — Leading pharmaceutical brands
Shu Xue Ning achieved by far the highest sales in China in 2009
Ke Lin Ao
Plavix — FDA ‘black box’ warning may influence its sales in China
China — Leading pharmaceutical companies
The leading international companies held almost 18% of Chinese value market in 2009
The leading domestic companies experienced impressive growth
Shandong Qilu Pharma
Jiangsu Yangzijiang Pharma
15. BIBLIOGRAPHY
[Missing title]
Publications and online articles
Datamonitor reports and products
US — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Japan — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
France — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Germany — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Italy — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Spain — Prescription pharmaceutical sales
Publications and online articles
Datamonitor reports and products
UK — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
Australia — Prescription pharmaceutical sales analysis
Publications and online articles
Brazil — Prescription pharmaceutical sales analysis
Publications and online articles
Russia — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
India — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
China — Prescription pharmaceutical sales analysis
Publications and online articles
Datamonitor reports and products
APPENDIX
Datamonitor prescription pharmaceutical definition and therapy area classification
- Global Medical Dressing Market
- Global Medication Management System Market 2012-2016
- ICT Spend Predictions in Large Brazilian Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large Canadian Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large French Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large German Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large Mexican Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large Spanish Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large UK Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Large US Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Brazilian Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Canadian Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized French Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized German Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Mexican Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized Spanish Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized UK Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Medium-sized US Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small Brazilian Healthcare Providers - Estimated ICT budget breakdowns in 2013
- ICT Spend Predictions in Small Canadian Healthcare Providers - Estimated ICT budget breakdowns in 2013
*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.
Für Sie protokollierte Studien / Marktanalysen:
zuletzt angesehene Studien:
Seite drucken
Seite empfehlen
Home | Werbung | Über marktforschung.de | AGB | Impressum | Sitemap | Suche © 2006 bis 2013 Alle Rechte bei marktforschung.de - Studie - Prescription Pharmaceutical Market Sales Overview – Analysis of prescription pharmaceutical sales across 12 major markets - Marktdaten / Marktanalysen bei marktforschung.de
